← Alle mensen

EN

Ernest Nadal

11 publicaties

PubMed → Google Scholar →

Publicaties op Oncologisch.com

Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non-Small Cell L...
Clinical cancer research : an official journal of the American Association for Cancer Research · 17 februari 2026
Biologie en klinisch management van non-V600 BRAF-alteraties bij NSCLC
Journal of Thoracic Oncology · 19 januari 2026
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
The New England journal of medicine · 19 juni 2025
RELAY: Final Totale overleving for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-04
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to Eerstelijns Pembro...
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-02
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab...
Clinical cancer research : an official journal of the American Association for Cancer Research · 15 november 2024
CZS-beschermend effect van selpercatinib bij eerstelijns RET-fusiepositief NSCLC
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 juli 2024
Bintrafusp alfa versus pembrolizumab bij PD-L1-hoog NSCLC: INTR@PID Lung 037 fase III
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023-12
Perioperatieve nivolumab plus chemotherapie bij stadium III NSCLC: CheckMate 77T fase III
The New England journal of medicine · 10 augustus 2023
RELAY subgroepanalyse naar EGFR-mutatietype: ramucirumab plus erlotinib bij NSCLC
Clinical cancer research : an official journal of the American Association for Cancer Research · 1 oktober 2021
Ramucirumab plus erlotinib bij onbehandeld EGFR-gemuteerd NSCLC: RELAY fase III
The Lancet. Oncology · 2019-12